Department of Medicine K2 Karolinska InstitutetCardiology Unit Stockholm Sweden.
Department of Research and Development Region KronobergVäxjö Sweden.
J Am Heart Assoc. 2021 Nov 16;10(22):e022667. doi: 10.1161/JAHA.121.022667. Epub 2021 Oct 30.
Background Dysglycemia at acute myocardial infarction (AMI) is common and is associated with mortality. Information on other outcomes is less well explored in patients without diabetes in a long-term perspective. We aimed to explore the relationship between admission glucose level and long-term outcomes in patients with AMI without diabetes in a nationwide setting. Methods and Results Patients without diabetes (n=45 468) with AMI registered in SWEDEHEART (Swedish Web-System for Enhancement and Development of Evidence-Based Care in Heart Disease Evaluated According to Recommended Therapies) and admission glucose ≤11 mmol/L (≤198 mg/dL) were followed for outcomes (AMI, heart failure, stroke, renal failure, and death) between 2012 and 2017 (mean follow-up time 3.3±1.7 years). The association between categorized glucose levels and outcomes was assessed in adjusted Cox proportional hazards regression analyses (glucose levels 4.0-6.0 mmol/L [72-109 mg/dL] as reference). Further nonfatal complications and their associated mortality were explored (patients without events served as a reference). A glucose level of 7.8-11.0 mmol/L (140-198 mg/dL) was associated with hospitalization for heart failure (hazard ratio [HR] 1.40 [95% CI, 1.30-1.51], <0.001), renal failure (1.17; 1.04-1.33, =0.009), and death (1.31; 1.20-1.43, <0.001), but not with recurrent myocardial infarction (0.99; 0.92-1.07, =0.849) or stroke (1.03; 0.88-1.19, =0.742). Renal failure had the strongest association with future mortality (age-adjusted HR 4.93 [95% CI, 4.34-5.60], <0.001), followed by heart failure (3.71; 3.41-4.04, <0.001), stroke (3.39; 2.94-3.91, <0.001), and myocardial infarction (2.08; 1.88-2.30, <0.001). Conclusions Elevated glucose levels at AMI admission identifies patients without diabetes at increased risk of long-term complications: in particular, hospitalization for heart and renal failure. These results emphasize that glucose levels at admission could be useful in risk assessment after myocardial infarction.
急性心肌梗死(AMI)时的糖代谢异常很常见,并且与死亡率相关。在长期观察中,对于无糖尿病的患者,其他结局的信息研究较少。我们旨在探讨在全国范围内,AMI 无糖尿病患者入院时血糖水平与长期结局的关系。
在 SWEDEHEART(根据推荐疗法评估的瑞典心脏病增强和发展的基于证据的护理网络系统)中登记的 AMI 无糖尿病(n=45468)患者,入院时血糖≤11mmol/L(≤198mg/dL),随访时间为 2012 年至 2017 年之间的结局(AMI、心力衰竭、卒中和肾衰竭以及死亡)(平均随访时间 3.3±1.7 年)。采用校正 Cox 比例风险回归分析评估分类血糖水平与结局的关系(血糖水平 4.0-6.0mmol/L[72-109mg/dL]作为参考)。进一步探讨了非致命性并发症及其相关死亡率(无事件患者作为参考)。血糖水平为 7.8-11.0mmol/L(140-198mg/dL)与心力衰竭住院(危险比[HR]1.40[95%CI,1.30-1.51],<0.001)、肾衰竭(1.17;1.04-1.33,=0.009)和死亡(1.31;1.20-1.43,<0.001)相关,但与复发性心肌梗死(0.99;0.92-1.07,=0.849)或卒中等(1.03;0.88-1.19,=0.742)无关。肾衰竭与未来死亡率的相关性最强(年龄调整后的 HR 4.93[95%CI,4.34-5.60],<0.001),其次是心力衰竭(3.71[3.41-4.04],<0.001)、卒中等(3.39[2.94-3.91],<0.001)和心肌梗死(2.08[1.88-2.30],<0.001)。
AMI 入院时血糖升高可识别出糖尿病患者,这些患者有发生长期并发症的高风险:特别是心力衰竭和肾衰竭住院。这些结果强调,入院时的血糖水平可用于心肌梗死后的风险评估。